2011

A conversation with Joseph Kim, MD, MPH, VP of Medical Affairs and Technology at Medical Communications Media, Inc., about the rapid development of mobile medical applications and the legal and regulatory issues that physicians, patients, and pharma developers/sponsors should be aware of.

Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.

This article focuses on Adobe Connect for eDetailing, a specific collaboration between Adobe and ConnectSolutions, a leading provider of private cloud deployments of web conferencing and collaboration solutions.

Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.

Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.

How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?

This article summarizes Eli Lilly's European experience using TeleWeb e-detailing, which combines a personal sales rep phone call with Web site surfing.

Economic Experts Disagree Wildly on How Much It Costs to Bring a New Drug to Market. How is it that the Tufts estimate is at least 14 TIMES the London School of Economics and Political Science (LSEPS) estimate? 'Make no mistake,' said Tufts. 'Tufts CSDD will vigorously defend the scholarship, integrity, and validity of all its published research studies.'

Welcome to Volume 10, Issue #8 (28 APRIL 2011) of Pharma Marketing News.

In a recent blog post, PhRMA said 'Without Promotion Research will be Useless.' To support its case, PhRMA cited 'an interesting opinion editorial' in the latest edition of the Annals of Emergency Medicine -- the medical journal of the American College of Emergency Physicians (ACEP). In the op-ed, entitled 'Limiting Gifts, Harming Patients,' Emory University economist Paul Rubin, Ph.D. expressed concern that ACEP policy regarding Gifts to Emergency Physicians from Industry 'could have the unfortunate effect of limiting the exchange of critical information between medicine makers and physicians about the benefits and risks of new medicines, how to use them properly and how best to diagnose the right candidates for particular treatments.'